Last reviewed · How we verify

Ropivacaine + saline solution

Federal University of Minas Gerais · FDA-approved active Small molecule Under review

Ropivacaine + saline solution is a Local anesthetic (amide class) Small molecule drug developed by Federal University of Minas Gerais. It is currently FDA-approved for Local infiltration anesthesia, Peripheral nerve blocks, Regional anesthesia procedures. Also known as: Naropin + saline solution.

Ropivacaine blocks sodium channels in nerve cell membranes to produce local anesthesia, with saline solution serving as the vehicle for delivery and dilution.

Ropivacaine is a small molecule used in medical interventions, including transversus abdominis plane blocks for conditions such as colorectal neoplasms, cardiac surgery, and acute pain. When combined with saline solution, ropivacaine is administered via transversus abdominis plane blocks in various clinical trials, including those for elderly patients undergoing abdominal surgery.

At a glance

Generic nameRopivacaine + saline solution
Also known asNaropin + saline solution
SponsorFederal University of Minas Gerais
Drug classLocal anesthetic (amide class)
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Ropivacaine is a long-acting amide local anesthetic that reversibly inhibits sodium influx into nerve fibers, preventing depolarization and action potential propagation. The saline solution formulation allows for appropriate concentration, osmolarity, and sterile delivery of the anesthetic agent to the site of administration. This combination is used for infiltration, nerve blocks, and regional anesthesia procedures.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Ropivacaine + saline solution

What is Ropivacaine + saline solution?

Ropivacaine + saline solution is a Local anesthetic (amide class) drug developed by Federal University of Minas Gerais, indicated for Local infiltration anesthesia, Peripheral nerve blocks, Regional anesthesia procedures.

How does Ropivacaine + saline solution work?

Ropivacaine blocks sodium channels in nerve cell membranes to produce local anesthesia, with saline solution serving as the vehicle for delivery and dilution.

What is Ropivacaine + saline solution used for?

Ropivacaine + saline solution is indicated for Local infiltration anesthesia, Peripheral nerve blocks, Regional anesthesia procedures.

Who makes Ropivacaine + saline solution?

Ropivacaine + saline solution is developed and marketed by Federal University of Minas Gerais (see full Federal University of Minas Gerais pipeline at /company/federal-university-of-minas-gerais).

Is Ropivacaine + saline solution also known as anything else?

Ropivacaine + saline solution is also known as Naropin + saline solution.

What drug class is Ropivacaine + saline solution in?

Ropivacaine + saline solution belongs to the Local anesthetic (amide class) class. See all Local anesthetic (amide class) drugs at /class/local-anesthetic-amide-class.

What development phase is Ropivacaine + saline solution in?

Ropivacaine + saline solution is FDA-approved (marketed).

What are the side effects of Ropivacaine + saline solution?

Common side effects of Ropivacaine + saline solution include Injection site reactions (pain, erythema), Systemic toxicity (CNS effects: dizziness, tinnitus, seizures), Cardiovascular effects (hypotension, bradycardia), Allergic reactions.

What does Ropivacaine + saline solution target?

Ropivacaine + saline solution targets Voltage-gated sodium channels and is a Local anesthetic (amide class).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing